SG Americas Securities LLC Purchases 37,140 Shares of Amgen Inc. (NASDAQ:AMGN)

SG Americas Securities LLC raised its holdings in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 348.5% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 47,798 shares of the medical research company's stock after purchasing an additional 37,140 shares during the quarter. SG Americas Securities LLC's holdings in Amgen were worth $14,891,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. Centricity Wealth Management LLC bought a new stake in shares of Amgen during the fourth quarter valued at about $25,000. Pinney & Scofield Inc. bought a new stake in shares of Amgen during the fourth quarter valued at about $26,000. Ritter Daniher Financial Advisory LLC DE increased its position in shares of Amgen by 66.2% during the fourth quarter. Ritter Daniher Financial Advisory LLC DE now owns 128 shares of the medical research company's stock valued at $33,000 after buying an additional 51 shares during the period. Synergy Investment Management LLC bought a new stake in shares of Amgen during the fourth quarter valued at about $34,000. Finally, Atala Financial Inc bought a new stake in shares of Amgen during the fourth quarter valued at about $34,000. 76.50% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, SVP Rachna Khosla sold 1,500 shares of Amgen stock in a transaction dated Thursday, June 5th. The stock was sold at an average price of $289.68, for a total value of $434,520.00. Following the completion of the sale, the senior vice president now directly owns 8,162 shares in the company, valued at approximately $2,364,368.16. This trade represents a 15.52% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.76% of the stock is owned by corporate insiders.

Amgen Trading Down 0.7%

AMGN stock traded down $2.07 on Friday, reaching $295.22. The company's stock had a trading volume of 2,191,182 shares, compared to its average volume of 2,820,660. Amgen Inc. has a 12-month low of $253.30 and a 12-month high of $346.85. The company has a debt-to-equity ratio of 9.62, a quick ratio of 0.95 and a current ratio of 1.26. The business has a fifty day simple moving average of $281.33 and a two-hundred day simple moving average of $285.58. The firm has a market cap of $158.74 billion, a PE ratio of 39.10, a PEG ratio of 2.63 and a beta of 0.51.

Amgen (NASDAQ:AMGN - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The medical research company reported $4.90 earnings per share for the quarter, beating the consensus estimate of $4.18 by $0.72. Amgen had a return on equity of 176.32% and a net margin of 12.24%. The firm had revenue of $8.15 billion during the quarter, compared to the consensus estimate of $8.05 billion. During the same period last year, the company earned $3.96 earnings per share. The company's revenue was up 9.4% on a year-over-year basis. As a group, research analysts forecast that Amgen Inc. will post 20.62 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on AMGN. Cantor Fitzgerald began coverage on Amgen in a research report on Tuesday, April 22nd. They set a "neutral" rating and a $305.00 price target on the stock. Morgan Stanley restated an "equal weight" rating on shares of Amgen in a research report on Friday, May 2nd. Johnson Rice set a $294.00 price objective on shares of Amgen in a research report on Wednesday, March 5th. Royal Bank of Canada decreased their price objective on shares of Amgen from $324.00 to $320.00 and set an "outperform" rating on the stock in a research report on Friday, May 2nd. Finally, Guggenheim started coverage on shares of Amgen in a research report on Tuesday, May 20th. They issued a "neutral" rating and a $288.00 price objective on the stock. Two investment analysts have rated the stock with a sell rating, twelve have issued a hold rating, nine have given a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, Amgen presently has a consensus rating of "Hold" and a consensus target price of $309.22.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.